Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105058 | 0.84 | CNR2 (0.52) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL105413 | 0.84 | TAS1R3 (0.53) | CNR2MAPK14NPC1RAB9AHPGD | |
| SCHEMBL104336 | 0.84 | CNR2 (0.55) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13823645 | 0.82 | MAPK14 (0.55) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10282601 | 0.82 | GLA (0.64) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13816273 | 0.82 | CNR2 (0.59) | CNR2NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL13122961 | 0.80 | TAS1R3 (0.63) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19651836 | 0.78 | MAPK14 (0.53) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27025556 | 0.78 | HTT (0.50) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL14568525 | 0.78 | MEN1 (0.54) | CNR2MAPK14NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CNR2 1750/4885MAPK14 1421/4885NPC1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.